Ligand id: 7580

Name: ocrelizumab

No information available.
Summary of Clinical Use
The US FDA had granted breakthrough therapy designation for ocrelizumab for the treatment of primary progressive multiple sclerosis which converted to full FDA approval for the treatment of relapsing and primary progressive types of multiple sclerosis in March 2017. Phase III clinical trials eg NCT01194570 and NCT01247324 were used to evaluate ocrelizumab clinical potential.

Development of this antibody as a treatment for other inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, and B-cell malignancies has been suspended [2-3].
Mechanism Of Action and Pharmacodynamic Effects
Ocrelizumab selectively targets CD20-positive B-cells which are implicated in the inflammatory and neurodegenerative processes of multiple sclerosis (MS). By targeting just these cells, the aim of this treatment is to be effective whilst leaving immune surveillance intact.